These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 33318007)
1. Keating CL; Zuckerman JB; Singh PK; McKevitt M; Gurtovaya O; Bresnik M; Marshall BC; Saiman L Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318007 [TBL] [Abstract][Full Text] [Related]
2. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109 [TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781 [TBL] [Abstract][Full Text] [Related]
4. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM; J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537 [TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL; Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081 [TBL] [Abstract][Full Text] [Related]
9. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF). Frost F; Young GR; Wright L; Miah N; Smith DL; Winstanley C; Walshaw MJ; Fothergill JL; Nazareth D J Cyst Fibros; 2021 Nov; 20(6):994-1002. PubMed ID: 33358119 [TBL] [Abstract][Full Text] [Related]
10. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Elborn JS; Henig NR Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195 [TBL] [Abstract][Full Text] [Related]
12. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296 [TBL] [Abstract][Full Text] [Related]
13. Inhaled aztreonam lysine: an evidence-based review. Hutchinson D; Barclay M; Prescott WA; Brown J Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352 [TBL] [Abstract][Full Text] [Related]